Preferred Label : PLK4 Inhibitor RP-1664;
NCIt definition : An orally bioavailable inhibitor of polo-like kinase 4 (PLK4), with potential antineoplastic
activity. Upon oral administration, PLK4 inhibitor RP-1664 selectively inhibits PLK4,
which results in the disruption of mitosis and the induction of apoptosis. This inhibits
the proliferation of tumor cells that overexpress PLK4 and/or tripartite motif-containing
protein 37 (TRIM37). PLK4, a member of the polo family of serine/threonine kinases
overexpressed in a variety of cancer cell types, plays a crucial role in the regulation
of centriole duplication during the cell cycle. Tumors with a high level of the E3
ubiquitin-protein ligase TRIM37 rely on PLK4 for survival.;
Molecule name : RP-1664; RP 1664;
NCI Metathesaurus CUI : CL1928216;
Origin ID : C205920;
concept_is_in_subset
- has_target
